Ulcerative colitis trials recruiting in Massachusetts
All Ulcerative colitis trials nationally
19
Recruiting in Massachusetts
7
Cities with sites
Cities in Massachusetts
Boston 14Chestnut Hill 2New Bedford 2Waltham 2Worcester 2Framingham 1Springfield 1
Recruiting trials in Massachusetts
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis
- Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
- High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
- Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Study of Novel Therapeutics for Acute Remedy of Colitis
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Treatment of UC With Novel Therapeutics
- Zymfentra (Infliximab-dyyb) REal World Cohort STudy